Tailored therapy could boost outcomes in elderly myeloma patients
NCT ID NCT06099912
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a personalized treatment plan for people aged 65 and older with newly diagnosed multiple myeloma. The treatment is adjusted based on each patient's frailty level to improve effectiveness and reduce side effects. About 131 participants will receive a combination of drugs including daratumumab, and researchers will track how well the cancer responds and how many patients stop treatment due to intolerance.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FRAILTY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Hospital of Jilin University
RECRUITINGChangchun, Jilin, 130021, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Smart sensors at home could spot frailty early and lend a helping hand
- Could muscle loss predict blood cancer outcomes?
- Can a Triple-Action antibody deepen remissions in myeloma?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Talking about the end: could guided conversations reduce futile cancer treatments?